ADMA Biologics, Inc. — Form 10-Q Summary
Business context and reporting period
ADMA is a late-stage biopharmaceutical company developing plasma-based biologics for immune-compromised patients. Its lead candidate, RI-002, is intended to treat primary immune deficiency disease. The company also operates FDA-licensed and internationally certified plasma collection operations in Georgia. This unaudited filing covers the three months ended March 31, 2015, compared with the three months ended March 31, 2014.
Key financial metrics
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Total revenue | $1.503 million | $1.561 million | Down 4% |
| Product revenue | $1.484 million | $1.542 million | Down 4% |
| Gross profit | $0.593 million | $0.584 million | Up 2% |
| Gross margin | Approximately 39.5% | Approximately 37.4% | Improved |
| Research and development expense | $1.402 million | $4.330 million | Down 68% |
| Total operating expenses | $4.705 million | $7.245 million | Down 35% |
| Loss from operations | $3.202 million | $5.684 million | Loss narrowed |
| Net loss | $3.606 million | $5.904 million | Loss narrowed 39% |
| Basic and diluted loss per share | $0.37 | $0.64 | Improved |
| Net cash used in operating activities | $4.221 million | $5.040 million | Use decreased |
Operating and net margins remained substantially negative because revenue was primarily from plasma sales and license revenue, while the company continued to fund product development, plasma-center expansion and commercialization activities.
- Cash and cash equivalents were $16.6 million at March 31, 2015, compared with $17.2 million at December 31, 2014.
- Short-term investments increased to $11.5 million from $4.7 million.
- Working capital was approximately $27.2 million.
- Total assets were $33.9 million and total liabilities were $20.5 million.
- Notes payable, net of debt discount, were $14.9 million. The Hercules debt carries an annual interest rate of at least 8.75%, plus 1.95% payment-in-kind interest, with principal repayments scheduled to begin October 1, 2015 and maturity no later than January 1, 2018.
- Cash provided by financing activities was $10.5 million, principally from the March 2015 common-stock offering.
Material changes versus the prior comparable period
- R&D expense declined by $2.9 million as the Phase III RI-002 clinical study was completed in the fourth quarter of 2014 and clinical manufacturing was completed during the first quarter of 2014.
- Plasma-center operating expenses increased 31% to $1.048 million, primarily because the second Georgia collection facility opened in late 2014 and donor collections increased.
- General and administrative expense increased 19% to $1.346 million because of commercialization planning, market research and higher stock-based compensation.
- Interest expense increased to $0.476 million from $0.227 million because of higher debt and related debt-discount and financing-cost amortization.
- Revenue declined modestly and remained substantially dependent on one customer, principally under the plasma supply arrangement with Biotest.
- In March 2015, ADMA issued 1,408,750 common shares at $8.00 per share, including the fully exercised over-allotment, generating gross proceeds of approximately $11.3 million and net proceeds of approximately $10.2 million. Shares outstanding increased to 10.7 million at March 31, 2015 from 9.3 million at year-end 2014.
- The Hercules warrant liability decreased from $476,760 at December 31, 2014 to $408,900, producing a $67,860 favorable change in fair value. The liability was reclassified to additional paid-in capital when the applicable down-round protection expired.
Guidance, outlook, risks and unusual items
- Management expected cash, cash equivalents and short-term investments at March 31, 2015 to fund operations into the first half of 2016, based on projected 2015 revenues and expenses.
- Management expected R&D expense to remain lower throughout 2015, while G&A expense was expected to rise because of commercialization planning and additional hiring.
- The company expected to file an RI-002 Biologics License Application during the first half of 2015. It stated that potential approval could occur within approximately one year of filing and that first commercial sales could occur as early as the first half of 2016, although these outcomes were uncertain.
- RI-002’s Phase III trial enrolled 59 patients and reportedly achieved its primary endpoint, with no serious bacterial infections observed during the trial. Regulatory approval, commercialization and revenue generation remained subject to FDA review and additional execution risks.
- The Marietta, Georgia plasma center was operating pending regulatory licensure and certification. Plasma collected there could not be sold until the applicable approval was obtained.
- The company had incurred cumulative losses of approximately $73.1 million since inception and had experienced negative operating cash flow since 2004. It stated that additional capital may be required sooner than anticipated if revenue, expense or development assumptions change.
- Potential financing alternatives included equity, debt, bank facilities, collaborations and licensing arrangements. No commitment for future external funding existed, and additional financing could be unavailable or dilutive.
- Hercules debt is secured by company assets other than intellectual property, is subject to financial and operational covenants, and may be accelerated upon specified defaults.
- Minimum rent obligations under the Georgia facility leases totaled approximately $3.2 million through the lease expirations in 2023 and 2024.
- Management stated that existing legal proceedings were not expected to have a material adverse effect. Disclosure controls were deemed effective as of March 31, 2015.
Important facts for investors to verify
- Whether the RI-002 BLA was filed during the first half of 2015 and the status, timing and conditions of FDA review.
- Whether RI-002 achieved approval and commercial launch milestones, and whether projected first-half 2016 sales materialized.
- The sustainability and concentration of plasma revenue, including the terms and status of the Biotest supply agreement.
- The licensing status and operating economics of the Marietta plasma collection center.
- Actual cash burn, capital needs and liquidity relative to management’s first-half 2016 funding estimate.
- The company’s ability to meet Hercules principal repayments beginning October 2015 and comply with its debt covenants.
- Further equity issuance, dilution and the effect of outstanding options and warrants, including approximately 1.5 million potentially dilutive securities at March 31, 2015.
- Changes in regulatory, clinical, manufacturing, reimbursement and competitive risks affecting RI-002 commercialization.